| abstract |
The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases, such as proliferative diseases, including but not limited to solid or liquid cancers, adenocarcinomas, Colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung cancer, non-small cell lung cancer and lung adenocarcinoma, acute myeloid lung cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, endometrial cancer, Gastric cancer, head and neck cancer, kidney cancer, leukemia, myelodysplastic syndrome, myeloid leukemia, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, testicular cancer, thyroid cancer, and cardiofacial skin (CFC) syndrome and Noonan syndrome, and similar and related disorders. |